INSIGHT: A Phase 3, Randomized, Open-Label Study of Ripretinib vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumor Previously Treated with Imatinib with Kit Exon 11 + 17/18 Mutations

Safety, Efficacy, and Patient-Reported Outcomes with Vimseltinib in Patients with Tenosynovial Giant Cell Tumor Who Received No Prior Anti-Colony-Stimulating Factor 1 Therapy: Ongoing Phase 2 Update.

Safety, Efficacy, and Patient-Reported Outcomes with Vimseltinib in Patients with Tenosynovial Giant Cell Tumor Who Received Prior Anti-Colony-Stimulating Factor 1 Therapy: Ongoing Phase 2 Update

DCC-2618, a novel pan-KIT and PDGFRα Kinase switch control inhibitor demonstrates encouraging activity in patients (pts) with Gastrointestinal Stromal Tumors (GIST). 

Phase 1 study of DCC-3014 to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with malignant solid tumors and diffuse-type tenosynovial giant cell tumor. 

INVICTUS, A Phase 3, interventional, double blind, placebo controlled study to assess the safety and efficacy of ripretinib (DCC 2618) in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior anticancer therapies.

Clinical benefit with ripretinib as ≥fourth-line treatment in patients with advanced gastrointestinal stromal tumor: Update from the phase 3 INVICTUS study. 

Ripretinib Intra-Patient Dose Escalation Following Disease Progression Provides Clinically Meaningful Progression-Free Survival in Gastrointestinal Stromal Tumor in Phase 1 Study. 

Characterization of the extensive heterogeneity of KIT/PDGFRA mutations in patients with fourth-line advanced gastrointestinal stromal tumor: Genomic analysis of the phase 3 INVICTUS study.

Ripretinib demonstrated activity across all KIT/PDGFRA mutations in patients with fourth-line advanced gastrointestinal stromal tumor: Analysis from the phase 3 INVICTUS study.